Articles On Paradigm Biopharmaceuticals (ASX:PAR)

The share price of Paradigm Biopharmaceuticals Ltd (ASX: PAR) is down today on an update of its new drug application. What does this mean for the Paradigm share price? Paradigm has repurposed an anti-inflammatory drug called pentosan polysu...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has started the week in the red. In morning trade, the clinical stage biopharmaceutical company’s shares are down just under 5% to $2.44. Why is the Paradigm share price sinking lo...

The FDA was unable to provide all questions within the initial IND review period and has advised it will submit further questions to Paradigm within the next 30 days.

The study will investigate changes in knee synovial fluid biomarkers associated with pain, inflammation and disease progression of knee Osteoarthritis.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a positive performer on Wednesday. In morning trade, the biopharmaceutical company’s shares are up 3% to $2.65. Why is the Paradigm share price charging higher? Investors...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Source:Ratanapon Srisuneton, Shutterstock Summary Opthea gets an iPSP waiver from the FDA for its lead product candidate to treat wet AMD. Paradigm and bene pharmaChem set to collaborate for the development of iPPS and other formulati...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the rise this morning following a partnership agreement. At the time of writing, the biopharmaceutical company’s shares are up 1.92% to $2.66. What did Paradigm announce? Par...

Source: Source: janews , Shutterstock   Healthcare takes over 1/10th per cent of the GDP of the most developed countries and the US contributes the most to this industry. As the coronavirus pandemic hit hard every industry, including hea...

The Paradigm Biopharmaceuticals Ltd [ASX:PAR] share price is up more than 4%, trading at $2.51. The PAR share price has largely traded sideways since October... The post Paradigm Biopharmaceuticals Shares Up on IND Application (ASX:PAR) app...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.45% to 6,820.8 points. Four ASX shares that are climbing more than most...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher on Friday. In early afternoon trade the biopharmaceutical company’s shares are up a sizeable 6% to $2.55. Why is the Paradigm share price charging higher today?...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce. The share price increase comes after Paradigm released its 1HY21 financial results. Here’s the rundow...

Paradigm is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury and inflammation.

The Phase 2 study will evaluate the treatment effect of Pentosan Polysulfate Sodium (PPS) (Zilosul®) compared with placebo on synovial fluid biomarkers in participants with knee osteoarthritis pain.

The company continues to progress toward submission of the investigational new drug for Zilosul® and is focused on implementation of the osteoarthritis clinical program to support commercialisation.

Summary ASX 300-listed Paradigm Biopharmaceuticals disclosed ongoing data for Zilosul® treatment under the SAS. The drug development player is firmly focused on the IND submission for its OA treatment this quarter. Paradigm also highl...

It has been a positive day of trade for the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price. In morning trade, the biopharmaceutical company’s shares jumped 8% higher to $2.70. Why did the Paradigm share price jump higher? The catal...

In the 89 patients treated with Zilosul®, 75.3% reported at least a 25% reduction in WOMAC pain with 56.2% of patients reporting a greater than 50% reduction, while in subjects with knee OA, it shows a very consistent reduction in pain of n...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are jumping higher today after the company provided an update prior to market open this morning. At the time of writing, the Paradigm share price is trading 1.2% higher at $2.50. What’s dri...

Summary ASX-300 Paradigm Biopharmaceuticals has obtained FDA’s response in favour of its OA treatment. The Company is finalising to submit IND to the FDA during Q1 CY2021. Paradigm has commenced preliminary work for its Phase 3 clinic...

The S&P/ASX 200 Index (ASX: XJO) looks set to end the week in a disappointing fashion. In late morning trade the benchmark index is down a sizeable 0.75% to 6,706.3 points. Four shares that have fallen more than most today are listed b...

In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher. At the time of writing, the biopharmaceutical company’s shares are up 2% to $2.59. Why is the Paradigm share price rising? Investors have been...

The same clinical trial protocol will be used in the US, Europe and Australia, potentially enabling registrations in multiple jurisdictions, saving time and money.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has come under pressure on Monday morning following the release of an update on its osteoarthritis (OA) clinical program. At the time of writing, the late stage drug development co...

The company is continuing the search for a person with extensive financial experience who will also be added to the board as an independent non-executive director.

The late-stage drug development company said the presentation would cover its proposed clinical program, safety and an update on other indications in the company’s R&D pipeline.

Summary ASX 300-listed Paradigm Biopharmaceuticals has started its Mucopolysaccharidosis type I (MPS-I) open-label Phase 2 clinical trial. The trial will assess the safety and tolerability of iPPS in MPS-I patients and will be conducted...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher today on news the company has started Phase 2 trials of pentosan polysulphate sodium (iPPS). In early morning trade, the Paradigm share price is up 1.62% to $3.1...

The trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.

Commercial head Beverley Huttmann, chief financial officer Justin Cahill and R&D scientist Catherine Stapledon bring skills and experience that further strengthen the capabilities of management as the company moves toward commercialisat...

Summary ASX 300 player Paradigm Biopharmaceuticals has reported additional positive data on patients who received Zilosul® under the Special Access Scheme (SAS) of the TGA. The Company anticipates providing information on further patien...

Pain reduction in 76 SAS patients (42 new patient data) being treated using the Phase 3 product are consistent with prior reports under TGA SAS.

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back strongly from yesterday’s surprise selloff. At the time of writing the benchmark index is up 1.35% to 5,894.3 points. Four shares that are climbing more...

01 Oct 2020 - Paradigm Biopharmaceuticals (ASX:PAR) report that patients receiving Zilosul reported a reduction in pain.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher again on Thursday. In morning trade the biopharmaceutical company’s shares are up a sizeable 9% to $2.89. This latest gain means the Paradigm share price is now...

Summary Paradigm Biopharmaceuticals’ supply agreement & exclusive licence with bene pharmaChem has been amended with positive & material commercial outcomes for bene pharmaChem is the only Pentosan Polysulphate Sodium (PPS) manuf...

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up slightly to 5,956.2 points. Four shares that are climbing more than most today...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a very strong performer on Tuesday. In morning trade the biopharmaceutical company’s shares are up a sizeable 12% to $2.70. Why is the Paradigm share price surging higher?...

The exclusive supply of Pentosan Polysulphate Sodium for 25 years following marketing approval provides a greater level of commercial protection for Paradigm as it progresses towards commercialisation of Zilosul® in Europe.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) updated the market today on its phase III trial and product registration in Europe. The news shot the Paradigm share price 8.3% higher to $2.47 at the time of writing. In comparison, the All Ordin...

Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is slightly higher today, up 0.38% at the time of writing to $2.66. This came after the company released its annual report for the year ended 30 June 2020. What were the FY20 resul...

The ASX is littered with small-cap shares all vying to be global leaders in their fields. These innovative start-up companies seek to pursue untapped market opportunities that could one day bring them to stardom like industry giants CSL Li...

Paradigm’s investigation of PPS for MPS seeks to establish whether PPS may be an effective adjunct/combination therapy with current Enzyme Replacement Therapy treatments.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...